Literature DB >> 29419439

Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.

Lorenzo Guglielmetti1,2,3, Linda Barkane4,5, Damien Le Dû3, Dhiba Marigot-Outtandy3,6, Jérôme Robert7,2, Nicolas Veziris7,2,8, Yazdan Yazdanpanah9, Liga Kuksa4,5, Eric Caumes10, Mathilde Fréchet-Jachym3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29419439     DOI： 10.1183/13993003.02550-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  10 in total

1.  A new era for treatment of drug-resistant tuberculosis.

Authors:  Neel R Gandhi; James C M Brust; N Sarita Shah
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

2.  Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Authors:  Zhiyi Lan; Nafees Ahmad; Parvaneh Baghaei; Linda Barkane; Andrea Benedetti; Sarah K Brode; James C M Brust; Jonathon R Campbell; Vicky Wai Lai Chang; Dennis Falzon; Lorenzo Guglielmetti; Petros Isaakidis; Russell R Kempker; Maia Kipiani; Liga Kuksa; Christoph Lange; Rafael Laniado-Laborín; Payam Nahid; Denise Rodrigues; Rupak Singla; Zarir F Udwadia; Dick Menzies
Journal:  Lancet Respir Med       Date:  2020-03-17       Impact factor: 30.700

Review 3.  New Drugs for the Treatment of Tuberculosis.

Authors:  Elisa H Ignatius; Kelly E Dooley
Journal:  Clin Chest Med       Date:  2019-12       Impact factor: 4.967

Review 4.  Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.

Authors:  Yang Li; Feng Sun; Wenhong Zhang
Journal:  Drug Dev Res       Date:  2018-12-11       Impact factor: 4.360

5.  INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES.

Authors:  Meseret T Asfaw; David L Holtzman; Gene F Kwan; Lawrence T Oyewusi; Carole D Mitnick; Kwonjune J Seung
Journal:  Afr J Infect Dis       Date:  2021-09-01

Review 6.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

Review 7.  Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review.

Authors:  Jahan Saeed Mallick; Parvati Nair; Elizabeth Tabitha Abbew; Armand Van Deun; Tom Decroo
Journal:  JAC Antimicrob Resist       Date:  2022-03-29

8.  Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.

Authors:  Helena Huerga; Uzma Khan; Mathieu Bastard; Carole D Mitnick; Nathalie Lachenal; Palwasha Y Khan; Kwonjune J Seung; Nara Melikyan; Saman Ahmed; Michael L Rich; Francis Varaine; Elna Osso; Makhmujan Rashitov; Naseem Salahuddin; Gocha Salia; Epifanio Sánchez; Armine Serobyan; Muhammad Rafi Siddiqui; Dri Grium Tefera; Dmitry Vetushko; Lusine Yeghiazaryan; David Holtzman; Shirajul Islam; Andargachew Kumsa; Gamarly Jacques Leblanc; Olga Leonovich; Shahid Mamsa; Mohammad Manzur-Ul-Alam; Zaw Myint; Shrivani Padayachee; Molly F Franke; Catherine Hewison
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

9.  WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?

Authors:  Nirmal Kumar Jain
Journal:  Lung India       Date:  2021 Jul-Aug

10.  Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.

Authors:  Erika Mohr; Jennifer Hughes; Anja Reuter; Laura Trivino Duran; Gabriella Ferlazzo; Johnny Daniels; Virginia De Azevedo; Yulene Kock; Sarah Jane Steele; Amir Shroufi; Serge Ade; Natavan Alikhanova; Guido Benedetti; Jeffrey Edwards; Helen Cox; Jennifer Furin; Petros Isaakidis
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.